The application of epigenetic modifiers on the treatment of prostate and bladder cancer.

Full Abstract

Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become a new area of cancer research. Agents such as deoxyribonucleic acid methyltransferase inhibitors or histone deacetylase inhibitors are epigenetic modifiers that can restore gene expression and alter the malignant phenotype of cancer. They provide a new therapeutic avenue for prostate cancer and TCC. It is also likely that combination regimens using epigenetic modifiers with other classes of agents may have higher therapeutic efficacy for prostate cancer and TCC, especially metastatic and/or refractory cases. We review current knowledge of epigenetic event in prostate cancer and TCC, and discuss the possible clinical implications for these 2 diseases.

Learn Faster Today Improve your study skills

Author information

Author/s: Zhang, Zhengwang (Z); Karam, Jose (J); Frenkel, Eugene (E); Sagalowsky, Arthur (A); Hsieh, Jer-Tsong (JT);

Affiliation: Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.

Grants: CA95730 (Agency:NCI NIH HHS)

Journal and publication information

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review

Journal: Urologic oncology (Urol Oncol), published in United States. (Language: eng)

Reference: -2006 Mar-Apr; vol 24 (issue 2) : pp 152-60

Dates: Created 2006/03/07; Completed 2006/10/26; Revised 2007/11/14;

PMID: 16520279, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Carcinoma, Transitional Cell - genetics; therapy
Epigenesis, Genetic
Gene Therapy
Histone Deacetylases - antagonists & inhibitors

Humans
Male
Prostatic Neoplasms - genetics; therapy
Urinary Bladder Neoplasms - genetics; therapy

Associated Chemicals: Histone Deacetylases (EC 3.5.1.-)

These are the highest related articles currently in the database:

See 100+ related articles.